Jim Finnel
Fallen Cannabis Warrior & Ex News Moderator
Tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors
A Zani,1 D Braida,1 V Capurro,1 and M Sala1*
1Department of Pharmacology, Chemotherapy and Medical Toxicology, Faculty of Sciences, University of Milan, Milan, Italy
*Author for correspondence: Email: mariaelvina.sala@unimi.it
Received July 25, 2007; Revised September 7, 2007; Accepted September 18, 2007.
Abstract
Background and purpose:
It has been suggested that the endocannabinoid system elicits neuroprotection against excitotoxic brain damage. In the present study the therapeutic potential of AM 404 on ischaemia-induced neuronal injury was investigated in vivo and compared with that of the classical cannabinoid receptor type 1 (CB1) agonist, Δ9-tetraydrocannabinol (THC), using a model of transient global cerebral ischaemia in the gerbil.
Experimental approach:
The effects of AM 404 (0.015—2mgkg−1) and THC (0.05—2mgkg−1), given 5min after ischaemia, were measured from 1h to 7 days in terms of electroencephalographic (EEG) total spectral power, spontaneous motor activity, memory function, rectal temperature and hippocampal CA1 neuronal count.
Key results:
Over the dose range tested, AM 404 (2mgkg−1) and THC (1mgkg−1) completely reversed the ischaemia-induced behavioural, EEG and histological damage. Only THC (1 and 2mgkg−1) induced a decrease of body temperature. Pretreatment with the selective CB1 receptor antagonist, AM 251 (1mgkg−1) and the opioid antagonist, naloxone (2mgkg−1) reversed the protective effect induced by both AM 404 and THC while the TRPV1 vanilloid antagonist, capsazepine (0.01mgkg−1), was ineffective.
Conclusions and implications:
Our findings demonstrate that AM 404 and THC reduce neuronal damage caused by bilateral carotid occlusion in gerbils and that this protection is mediated through an interaction with CB1 and opioid receptors. Endocannabinoids might form the basis for the development of new neuroprotective drugs useful for the treatment of stroke and other neurodegenerative pathologies.
Keywords: (Endo)cannabinoid, vanilloid, ischaemia, electroencephalogram, memory, motor activity, rectal temperature
Introduction
The therapeutic potential of the endocannabinoid system is yet to be fully determined, and the number of diseases that may be treated by interacting with this system will probably continue to grow (Sarne and Mechoulam, 2005; Bahr et al., 2006; Centonze et al., 2007). Until now the endocannabinoid system has been evaluated as a possible target for the treatment of several neurological disorders including Parkinson's disease (Lastres-Becker et al., 2005; Garcia-Arencibia et al., 2007; Kreitzer and Malenka, 2007), Huntington's disease (de Lago et al., 2006), neurodegeneration (Battista et al., 2006; Monory et al., 2006; Rotilio and Stella, 2006) and disorders associated with excessive excitatory neuronal activity, such as epilepsy. Endocannabinoids directly target hippocampal glutamatergic neurons to provide protection against acute epileptiform seizures in mice (Monory et al., 2006).
Special attention has been paid to the mechanism of endocannabinoid uptake through which the biological activity of endocannabinoids ceases (McFarland and Barker, 2004). These compounds, termed indirect agonists, act by potentiating the action of endogenous ligands, and hence they may be used in diseases where an increase in endocannabinoid transmission has been postulated to be of therapeutic value (Giuffrida et al., 2001; Pertwee, 2002). It may be possible to use these compounds to minimize the unwanted effects produced by the direct activation of cannabinoid receptor type 1 (CB1) receptors by classical cannabinoids, through the control of endocannabinoid levels in a concentration range that avoids psychoactive side-effects (Felder and Glass, 1998). One of these compounds, N-(4- hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (AM 404), an inhibitor of anandamide cellular reuptake and inactivation (Khanolkar et al., 1996; Beltramo et al., 1997), has been shown to provide some relief of symptoms associated with neurological disorders. AM404 produced a marked recovery of 6-hydroxydopamine-induced dopamine depletion and tyrosine hydroxylase deficit in the lesioned side of rats submitted to unilateral lesions of nigrostriatal dopaminergic neurons, induced by local application of 6-hydroxydopamine (Pertwee, 2005). Amelioration of akinesia and sensorimotor orientation and reduction of amphetamine-induced turning behaviour in 6-hydroxydopamine-lesioned rats has also been observed after an injection of AM 404 (Fernandez-Espejo et al., 2004). AM 404 significantly decreased restraint-induced serum corticosterone release in mice, suggesting a role of the endocannabinoid system in the signs of environmental stress (Patel et al., 2004; Patel and Hillard, 2006). AM 404 has also been shown to inhibit the anandamide transporter in rat brain neurons and slices (Beltramo et al., 1997; Beltramo and Piomelli, 2000) and human astrocytoma cells (Piomelli et al., 1999) in vitro. When given intravenously, AM 404 induced vasodilatation (Calignano et al., 1997) in guinea-pigs and enhanced and prolonged anandamide-induced analgesia (Beltramo et al., 1997) in mice, in vivo. However, exogenously administered AM404 did not elicit catalepsy or analgesia in rats (Beltramo et al., 2000), but was found to potentiate the effects of anandamide (Rodriguez de Fonseca et al., 2005). In Wistar rats, treatment with AM 404, at a dose of 10mgkg−1, was found to have a hypokinetic effect which was reversed by the CB1 receptor antagonist, rimonabant (Giuffrida et al., 2000). In addition, AM 404 (5mgkg−1) has been found to act as a psychodysleptic drug, altering prepulse inhibition in mice through a cannabinoid CB1 receptor (Fernandez-Espejo and Galan-Rodriguez, 2004) and elicit antidepressant-like effects in the forced swimming test in rats (Hill and Gorzalka, 2005).
There is some evidence from experiments with mice that increasing anandamide or 2-arachidonoyl glycerol content may lead to neuroprotection. After an excitotoxic insult in rat hippocampal slices, an infusion of the fatty acid amide hydrolase inhibitor palmitylsulphonyl fluoride (AM374) and AM404, in combination, protected against cytoskeletal damage and synaptic decline (Karanian et al., 2005, 2007). AM404 per se elicited cytoskeletal and synaptic protection in vivo when coinjected with excitotoxin into the dorsal hippocampus. The potentiated endocannabinoid responses also prevented alterations in behaviour and memory impairment that are characteristics of excitotoxic damage. These protective effects were blocked by a selective CB1 antagonist. The endocannabinoid 2-arachidonoyl glycerol is released in mouse brain after closed head injury, and treatment with exogenous 2-arachidonoyl glycerol exerts neuroprotection via the central CB1 receptor (Panikashvili et al., 2006).
AM404, structurally similar to transient receptor potential vanilloid type-1 (TRPV1) vanilloid receptor agonists, anandamide and capsaicin, may also activate vanilloid TRPV1 receptors (Zygmunt et al., 2000) and, then, exhibit direct effects by itself (Gonzalez et al., 1999; Beltramo and Piomelli, 1999). Capsaicin has been shown to effect neuroprotection through the activation of TRPV1 vanilloid receptors in a model of transient cerebral ischaemia in gerbils (Pegorini et al., 2005, 2006).
The aim of the present work was to assess the therapeutic potential of AM 404 in vivo, and compare its effects with those of the classical CB1 receptor agonist, Δ9-tetraydrocannabinol (THC), on ischaemia-induced neuronal injury using a model of transient global cerebral ischaemia in the gerbil. In principle, we aimed to inject the drugs 5min after ischaemia, as previously performed for other cannabinoid and vanilloid agonists (Braida et al., 2001, 2003; Pegorini et al., 2005, 2006) in order to compare their potential neuroprotective effects with those of previously tested drugs. To quantify the ischaemic damage, from 1h to 7 days after reperfusion, we measured different parameters known to be influenced by global cerebral ischaemia: electroencephalogram (EEG) spectral power, spontaneous motor activity, memory function and hippocampal CA1 neuronal count. We measured motor activity on day 1, since ischaemia-induced hyperlocomotion is maximal 24h after occlusion (Araki et al., 1986), memory function on day 3 according to Sala et al. (1997). Since the decrease in electroencephalogram has been related to pronounced damage of neurons on day 7 (Suzuki et al., 1983; Hunter et al., 1995; Peruche et al., 1995), EEG spectral power and neuronal counts were measured at that time. In addition, receptor antagonists were used to investigate a potential role for CB1, opioid and TRPV1 receptors. Collectively, our data demonstrate that AM 404 and THC protect against neuronal ischaemia-induced injury through a mechanism involving cannabinoid and opioid receptors but not vanilloid receptors.
Methods
Animals
Male Mongolian gerbils (Meriones unguiculatus) (Charles River, Calco, Como, Italy) weighing 60—80g were housed singly in standard laboratory conditions: air-conditioned room (22±2°C), 12-h light/12-h dark light cycle, free access to food and water. The gerbils were allowed to acclimatize themselves to the environment for 1 week before surgical implantation of cortical electrodes. After the EEG electrodes had been implanted, the gerbils were divided into different groups on the basis of the treatment assigned. Each animal received all tests. All procedures were approved under the Italian Governmental decree no. 32/2004.
Surgical procedure
Gerbils were anaesthetized with an i.p. injection of chloral hydrate (450mgkg−1) dissolved in saline and given in a volume of 9mlkg−1. Four electrodes (Bilaney, Dusseldorf, Germany) were implanted for EEG recordings, as described previously (Sala et al., 1997), on the right and left of the parieto-occipital cortex according to brain atlas coordinates (anterior +2, posterior −3, lateral 2, ventral 1.6 from bregma) (Loskota et al., 1974). Another electrode was inserted into the nasal bone as a reference location. The five electrodes were connected to a pedestal (Bilaney) and fixed with acrylic cement. The animals were allowed a week to recover from surgery before the experiments were started.
EEG recording
Freely moving, awake gerbils were acclimatized in a sound-proofed Faraday chamber, then their electroencephalogram was recorded for 1h a day, for 3 days, to determine the basal total and relative spectral power. The signals were recorded and processed for fast Fourier transform spectral analysis by means of PC software (PowerLab, AD Instruments Pty Ltd, Castle Hill, NSW, Australia). Electroen Cephalograph (EEG) recordings were also made during and 7 days after ischaemia. Each 1-h spectral power was calculated as the mean of six 1-min recordings taken at 10-min intervals.
Cerebral ischaemia
After basal EEG recordings, each gerbil was again lightly anaesthetized with 2,2,2- tribromoethanol (200mgkg−1, 10mlkg−1). Throughout surgery, body temperature was kept at 37°C with a heating lamp and 10-min period of ischaemia was induced by occlusion of the bilateral common carotid arteries, as described previously (Braida et al., 2000). The ischaemia was verified qualitatively on paper by the complete absence of the electroencephalogram. A group of animals (sham-operated) underwent the same surgical procedure except that the carotid arteries were not clamped.
Locomotor activity
Spontaneous motor activity was evaluated as described previously (Braida et al., 2000) in an activity cage (43cm long × 43cm wide × 32cm high: Ugo Basile, Varese, Italy), placed in a sound-proofed room. The cage was fitted with two parallel horizontal infrared beams 2cm off the floor. Cumulative horizontal movements were counted every 5min for 30min, 1 day after ischaemia.
Passive avoidance task
On the third day after ischaemia, each gerbil was examined in the passive avoidance task. The apparatus (Ugo Basile) consisted of a box divided by a guillotine door into two compartments of the same size (22cm long × 22cm wide × 21cm high) in which the floor was a stainless rod grid. One compartment was lit with a 10W electric light bulb, while the other was dark. The step-through type passive avoidance task was used, as described by Katoh et al. (1992), with some modifications. Animals were allowed to adapt for 10min before the training, and retention was checked 24h after the training. For the adaptation a gerbil was placed in the light compartment, and allowed to explore both compartments by leaving the guillotine door open for 5min. After 10min, the training period was started during which each gerbil was placed in the light compartment and allowed to enter the dark. When the gerbil entered the dark compartment, the door automatically closed and an unavoidable scrambled foot shock (1.5mA) was delivered for 5s. Each gerbil then stayed there for 10s. The procedure was immediately repeated twice. For the retention test, gerbils were placed in the light compartment and the latency period before they re-entered the dark compartment was recorded for up to 180s.
Body temperature
The experiments were performed in the sound-proofed Faraday chamber. Controls, sham-operated and ischaemic gerbils were trained to accept the temperature measurements for 5 days before thermoregulator reactions were tested, as described by Sala et al. (1997). Briefly, after a 1-h acclimatization period in the test room, maintained at 22°C, body temperature was monitored with a rectal thermistor probe (PRA-22002-A, Ellab, Roedovre, Denmark) inserted 3cm into the colon. After a 30-s equilibration period, the temperature was recorded to the nearest 0.11°C on a CTD 85-M Thermometer (Ellab). During temperature measurements, gerbils were unrestrained and were held gently by hand at the base of the tail. Temperature was measured three times (every 10min) before induction of ischaemia (basal) and again at 30, 60, 90 and 120min after recirculation.
Histology
Seven days after the ischaemic injury, all the gerbils were killed by an overdose of chloral hydrate 5% and transcardially perfused with 4% paraformaldehyde for determining histological data, as described previously (Braida et al., 2003). Brains were removed and placed in the same fixative overnight, then embedded in paraffin wax. Five serial 5-μm coronal hippocampal sections for each animal were cut at 1.5, 1.7 and 1.9mm caudal to the bregma, using a microtome (Leica, Mod. RM2125RT, Solms, Germany), and stained with cresyl violet. Neurons with a normal appearance in the pyramidal cell layer of the CA1 sector were counted blind (from coded slides) in each section for each group.
Experimental design
Gerbils submitted to ischaemia were divided into different groups, receiving acutely: vehicle+vehicle; vehicle+AM 404 (0.015, 0.03, 0.1, 0.5, 1, 2mgkg−1); AM 251 (1mgkg−1)+vehicle; AM 251+AM 404 (2mgkg−1); capsazepine (0.01mgkg−1)+vehicle; capsazepine+AM 404 (2mgkg−1); naloxone (2mgkg−1)+vehicle; naloxone+AM 404 (2mgkg−1); vehicle+THC (0.05, 0.1, 0.5, 1, 2mgkg−1); AM 251+THC (1mgkg−1); capsazepine+THC (1mgkg−1) and naloxone+THC (1mgkg−1). AM 404 and THC were injected i.p. 5min after recirculation; capsazepine was given s.c. 15min before bilateral carotid occlusion, while AM 251 and naloxone were given i.p. 5min before. Vehicle was given 15 or 5min before or 5min after ischaemia, either s.c. or i.p. Drugs were dissolved in an appropriate vehicle (90% saline–10% (dimethylsulphoxide) for AM 404 and AM 251; cremophor, ethanol, saline 1
18 for THC; Tween-80, ethanol, saline, 18 for capsazepine; saline for naloxone) and injected in a volume of 1mlkg−1 s.c. and 5mlkg−1 i.p. The sham-operated group received the same volume of vehicle. The dose of capsazepine used was chosen on the basis of our previous work (Pegorini et al., 2006), where it reversed the neuroprotection induced by capsaicin. The dose of naloxone used was able to antagonize the rewarding effects produced by heroin (Braida et al., 2001) and THC (Braida et al., 2004), while that of AM 251 reversed the anxiolytic effect induced by THC and AM 404 (unpublished data).
Statistical analysis
Data are presented as mean (±s.e.m.). Vehicle groups (s.c. and i.p) were pooled for analysis. Total EEG spectral data are expressed as the mean difference (%) from the pre-ischaemic values. Total spectral power, motor activity, latency time and neuronal counts were analysed by one- or two-way analysis of variance (ANOVA) for multiple comparisons, followed by Tukey's or Student's t-test. The accepted level of significance was P<0.05. All statistical analyses were carried out using Prism, version 4 software (GraphPad, USA).
Drugs, materials and sources
AM 404, AM 251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide), chloral hydrate, 2,2,2-tribromoethanol, paraformaldehyde, cresyl violet, naloxone and THC (Sigma Aldrich, St Louis, MO, USA); capsazepine (Tocris Bioscience, Bristol, UK); acrylic cement (Palavit, New Galetti and Rossi, Milan, Italy).
Results
Physiological parameters–food and water consumption and body weight (76.20±0.38g)–were stable throughout the study in all groups (data not shown).
EEG recordings
Seven days after a 10-min period of carotid occlusion and treatment with AM 404 or THC 5min after recirculation, a quantitative EEG analysis was performed in the ischaemic and sham-operated gerbils (Figures 1a and b). Significant between-group differences were
observed in terms of the percentages of the pre-ischaemic values of mean total spectral power, evaluated on day 7 after AM 404 (F(12,52)=28.27, P<0.0001, ANOVA) and THC (F(12,52)=11.49, P<0.0001, ANOVA) treatment. Post hoc analysis revealed that, in comparison with sham-operated values, the vehicle group had a decrease of EEG power of about 80%. AM404, at all the doses tested, while THC, in a range between 0.1 and 1mgkg−1, significantly antagonized the ischaemia-induced EEG flattening. Pretreatment with naloxone (2mgkg−1) completely, while pretreatment with AM 251 (1mgkg−1) or capsazepine (0.01mgkg−1) only slightly, blocked the protective effect of AM404 obtained at 2mgkg−1. Post hoc test showed that both AM 251 and naloxone, but not capsazepine, reversed the protective effect of THC. The three antagonists per se did not induce any changes, when compared with the vehicle group. Figure 1
Cortically derived EEG total spectral power evaluated on day 7, as the difference (Δ%) from the pre-ischaemic value in freely moving, awake gerbils given increasing doses (mgkg−1) of AM 404 (a) and THC (b), 5min (more ...)
Spontaneous locomotor activity
There were significant between-group changes in spontaneous locomotor activity 1 day after ischaemia in gerbils treated with AM 404 or THC (Figures 2a and b). ANOVA revealed significant differences
between groups after AM404 (F(12,52)=35.32, P<0.0001) and THC (F(12,52)=17.95, P<0.0001) treatment. Post hoc comparison revealed an increase in locomotor activity in the vehicle group compared to the sham-operated group, whereas a complete recovery in the activity levels was observed, at all the tested doses, in the AM 404 and THC-treated animals. Naloxone and AM 251 reversed the protective effect of AM 404 (2mgkg−1) but capsazepine had no effect. When combined with THC (1mgkg−1), AM 251 induced a partial but significant antagonism of the effects of THC. Capsazepine and naloxone failed to block the protective effect of THC. The three antagonists per se did not affect hyperlocomotion. Figure 2
Effect of increasing doses (mgkg−1) of AM 404 (a) and Δ9-THC (b) given i.p. 5min after recirculation on spontaneous motor activity evaluated for 30min, 1 day after ischaemia in gerbils. AM 251 or naloxone (NX) (more ...)
Passive avoidance
Figure 3 shows the mean latency time measured 3 days after
recirculation in ischaemic gerbils treated with increasing doses of AM 404 or THC (Figures 3a and b). There were significant between-group
changes in mean latency time in AM 404 (F(12,52)=6.18, P<0.0001, ANOVA) and THC (F(12,52)=143.9, P<0.0001, ANOVA) groups. Post hoc analysis indicated that vehicle-treated gerbils experienced significant impairment, as shown by the decrease in mean escape latency in comparison with the sham-operated group. AM404 and THC progressively improved, even if only slightly, this memory deficit. Pretreatment with AM 251 and capsazepine did not affect the cognitive improvement induced by AM 404 (2mgkg−1), whereas it was completely antagonized by naloxone (Tukey's test). When AM 251 and naloxone were given in combination with THC (1mgkg−1), complete antagonism of the effect of THC was observed (Tukey's test). Capsazepine failed to block the protective effect of THC. Figure 3
Mean (±s.e.m.) escape latency in the passive avoidance task 3 days after 10-min carotid occlusion. Increasing doses (mgkg−1) of AM 404 (a) and THC (b) given 5min after recirculation. AM 251 or naloxone (NX) was administered, (more ...)
Body temperature
Changes in body temperature were only seen at 30min after the period of ischaemia (2-way ANOVA, followed by Bonferroni's test). Thus, in Table 1 only findings obtained at 30min after ischaemia are presented.
Treatment with AM404 did not affect the mean rectal temperature at any dose tested, but THC did (F(12,52)=10.77, P<0.0001, ANOVA). Post hoc analysis revealed that in THC groups treated with 1 and 2mgkg−1 there was a decrease of body temperature. Pretreatment with AM 251 antagonized THC (1mgkg−1)-induced hypothermic effect while capsazepine and naloxone, which per se did not affect this parameter, were ineffective. Table 1
Effect of AM 404 and THC given alone or in combination with different antagonists on rectal temperature (°C) in gerbils subjected to cerebral ischaemiaa
Histology
Histological examination of the hippocampus at 7 days after recirculation, following 10min of occlusion and 5min of treatment, showed that severe alterations in the CA1 region occurred in the ischaemic group compared to the sham-operated animals (Figure 4).
Most of the pyramidal cells were darkly stained and shrunken. A comparison of the number of neuronal cells counted (using ANOVA) revealed significant differences between the groups (F(8,36)=23.78, P<0.0001 for AM 404 (2mgkg−1); F(8,36) =6.85, P<0.0001 for THC (1mgkg−1)). A post hoc analysis revealed a decreased number of neuronal cells in the vehicle-treated gerbils compared with the sham-operated group and both drugs completely prevented this loss of cells (Figure 5). Pretreatment with naloxone significantly antagonized AM
404-induced neuroprotective effect, whereas AM 251 and capsazepine failed to block it. The three antagonists per se caused a mean decrease in the number of neuronal cells similar to that seen in the vehicle-treated group. Only pretreatment with AM 251 significantly antagonized the neuroprotective affect of THC. Figure 4
Photomicrographs of the hippocampal CA1 region of gerbils with or without 10min ischaemia, 7 days after recirculation. AM 251 and naloxone (NX) were given, i.p., 5min before bilateral carotid occlusion; capsazepine (CPZ) was given, s.c., (more ...)
Figure 5
Effect of AM 404 (a) and THC (b) on neuronal count, performed 7 days after recirculation, in the CA1 region of the hippocampus of sham-operated or ischaemic gerbils. AM 404 and THC were given, i.p., 5min after recirculation. AM 251 or naloxone (more ...)
Discussion
In the present study, using a well-established animal model of ischaemia, we showed that both the exogenous cannabinoid agonist, THC, and the anandamide transporter inhibitor, AM 404, given i.p. after bilateral carotid occlusion, fully protected the animals from the deleterious effects of the ischaemic insult. This neuroprotection was quantified in terms of complete recovery of all the behavioural and EEG parameters. Among them, both cognitive and sensorimotor deficits can be found in some human pathological conditions, such as heart attack and coronary artery bypass surgery (Hunter et al., 1998). Furthermore, the histopathology seen in the gerbil is similar to that observed in the hippocampal CA1 region of human brain following cardiac arrest (Hunter et al., 1995).
Results obtained from EEG mean total spectral analysis indicated that both THC and AM 404 reversed EEG flattening effect (isoelectric electroencephalogram), induced by bilateral carotid occlusion on day 7 after ischaemia. It is known that after transient global ischaemia, EEG drop is indicative of a severe depression of electrophysiological activity and reflects an impairment of cerebral blood flow. Such a decrease has been related to the severe and selective neuronal death appearing in the CA1 layer of the hippocampal formation following an impairment of synaptic activity (Kirino and Sano, 1984; Smith et al., 1984; Zola-Morgan et al., 1986; Schmidt-Kastner and Hossmann, 1988).
Vasodilatation may be involved in the protection against neuronal death on day 7 effected by THC (1mgkg−1) and AM 404 (2mgkg−1). Cannabinoid perfusion increases the diameter of cerebral arterioles and cerebral arteries (Hillard, 2000) in a CB1 receptor-dependent fashion, indicating that the main cerebrovascular effect of cannabinoids is vasodilatation. This accords with findings that marijuana smoking in humans is accompanied by an increase in cerebral blood flow (Mathew et al., 2003). Furthermore, AM 404 has been found to be a vasodilator and activator of TRPV1 receptors expressed in Xenopus oocytes (Zygmunt et al., 2000) and in the rat hepatic artery (Zygmunt et al., 1999).
The full protection against motor hyperactivity seen in both THC and AM 404-treated gerbils indicates that these drugs induce a recovery of the ability of animals to form spatial maps, initially suppressed due to the loss of CA1 neurons, as suggested by O'Neill and Clemens (2000). Any intrinsic effects of the drugs can be excluded, since the evaluation was carried out 24h after treatment.
Both THC and AM 404 dose-dependently prevented ischaemia-induced memory impairment. This condition has been clinically demonstrated during cardiac arrest, revealed as amnesia and characterized by impaired learning and memory of events after the injury (Volpe and Hirst, 1983). The deficits in learning and memory induced by global cerebral ischaemia showed a close correlation with the neuronal death in the hippocampal CA1 region, as suggested by Block (1999). An increase in number of intact CA1 neurons (about 75%) that are most vulnerable to hypoxic insult and involved in learning and memory was observed in THC- and AM 404-treated gerbils subjected to ischaemic insult.
The protective effect of THC was accompanied by a clear hypothermic effect at the highest doses. At present, post-ischaemic hypothermia provides the best long-term functional and histological protection against the effects of global ischaemia (Colbourne and Corbett, 1995; Colbourne et al., 1999; Hickey et al., 2000). However, since THC exhibited neuroprotective effects at both hypothermic and normothermic doses, hypothermia was not a factor in this study. In addition, Louw et al. (2000) found that there was significantly less neocortical injury after induction of global cerebral ischaemia in THC-treated rats when rigorous temperature control was maintained through the experiment.
No change in body temperature was observed in AM 404-treated animals. This is in accordance with the results of Rawls et al. (2006); they demonstrated that this endocannabinoid inhibitor transporter produced a clear hypothermic effect, which required a vanilloid TRPV1 activation, only at doses higher than 10mgkg−1.
The neuroprotection obtained with THC is consistent with previous findings where other cannabinoids, like CP 55940 (Braida et al., 2000) and cannabidiol (Braida et al., 2003), prevented ischaemia-induced damage in the same animal model of ischaemia. In addition, after repeated treatment with THC for 7 days prior to bilateral carotid artery occlusion produced a neuroprotection in rats in vivo, accompanied by a reduction in systolic blood pressure (Louw et al., 2000). In in vitro studies, THC protected neurons against excitotoxic insults, mediated by exposure to the glutamatergic agonists N-methyl-D-aspartate and KA (Hampson et al., 1998; El-Remessy et al., 2003; Chen et al., 2005; Gilbert et al., 2007; Kreutz et al., 2007).
The neuroprotection obtained with AM 404 is in accordance with the findings of Karanian et al. (2005), who reported that the anandamide transporter inhibitor enhanced the action of exogenous anandamide in vitro protecting against excitotoxic damage in hippocampal slice cultures by a mechanism involving CB1 receptors. In addition, AM 404 repeatedly administered for 2 weeks produced a marked recovery of 6-OH-dopamine-induced dopamine depletion in a rat model of Parkinson's disease (Garcia-Arencibia et al., 2007).
The finding that AM 251 prevented neuroprotection induced by both THC and AM 404 indicates that CB1 receptors are involved in this effect. The antagonism by AM 251 of the neuroprotection induced by THC does not agree with the findings of other studies, where the protective actions of THC were mediated primarily or exclusively by effects on chemical antioxidants (Chen and Buck, 2000; Hampson et al., 2000, Marsicano et al., 2002). Therefore, it appears that in some circumstances, THC exerts neuroprotective effects exclusively through non-receptor-mediated antioxidant properties, while in other models stimulation of CB1 receptors by THC or WIN 55212-2 might produce neuroprotection. Differences between the effects observed in different models may be related to the cell type or model system, and to differences in the toxic insults employed.
As expected, capsazepine did not reverse the protective effect of THC. Accordingly, the neuroprotective effect of THC, evaluated in an in vitro model in which the AF5 CNS cell line was exposed to toxic levels of N-methyl-D-aspartate, was not reversed by the TRPV1 antagonist (Chen et al., 2005). In addition, THC-induced suppression of serum interleukin-12 levels in Legionella pneumophila-infected cells was not attenuated by pretreatment with the TRPV1 antagonist.
Although it has been shown that AM 404 binds TRPV1 receptors in the rat isolated hepatic artery (Zygmunt et al., 2000), it is unlikely that this occurred at the doses of this endocannabinoid transporter inhibitor used in our study. Activation of TRPV1 leads to an increased influx of Ca2+ (Szallasi and Blumberg, 1999), glutamate release (Marinelli et al., 2002) and substantial contribution to neuronal excitotoxicity (apoptosis) (Maccarrone et al., 2000; Hail, 2003; Yue et al., 2004). It could be argued that the dose of capsazepine used in the present study was too low to reverse any TRPV1-mediated effects. However, Costa et al. (2006) showed that capsazepine (10mgkg−1) reversed the antihyperalgesic effect of AM 404 in a rat model of neuropathic pain. In addition, Tzavara et al. (2006) found that 5mgkg−1 capsazepine were able to antagonize the normalization of hyperlocomotion induced by AM 404 (3mgkg−1) in a model of hyperdopaminergia in knockout mice. However, in our experiments, using our model of global ischaemia, when the dose was increased (0.05mgkg−1) capsazepine exhibited per se a protective effect (data not shown). This latter finding is in accordance with previous results (Veldhuis et al., 2003) where the vanilloid antagonist per se reduced brain injury caused by excitotoxicity, and when given in a range of doses between 0.005 and 5μmolkg−1 (Akabori et al., 2007) (similar to ours) it significantly improved survival rates in a rat model of haemorrhagic shock.
The opioid antagonist, naloxone, blocked the neuroprotective effect induced by THC in terms of EEG flattening and memory impairment, and that induced by AM 404 on all the parameters evaluated. An interaction between the opioid and endocannabinoid system is not surprising since cannabinoids and opioids share several pharmacological effects, including hypothermia, sedation, analgesia and the inhibition of motor activity (Bloom and Dewey, 1978; Manzanares et al., 1999). Systemic administration of THC increases extracellular levels of the endogenous opioid receptor ligand β-endorphin in both the ventral tegmental area and the nucleus accumbens, and injection of β-endorphin into the ventral tegmental area markedly enhances the ability of rats to discriminate the effects of experimenter-administered THC (Solinas et al., 2004). In addition, it has been shown that CB1 receptors and μ- and δ-opioid receptors in the striatum are strongly linked at the intracellular level (Berrendero et al., 2003). Thus, on the one hand, cannabinoid receptor agonists can release endogenous opioids, and, on the other hand, stimulation of opioid receptors can facilitate the signal transduction of cannabinoid receptors. Therefore, it is likely that opioid agonists facilitate certain effects of THC by mimicking some of the effects of endogenous opioids released by THC and, at the same time, facilitating CB1 receptor-induced effects at the intracellular level. Conversely, the reduction of the protective actions of THC, induced by opioid antagonists, is probably due to blockade of the effects of endogenous opioids released by THC and antagonism of CB1 receptor-mediated effects at the intracellular level.
To summarize, our findings provide further evidence for the involvement of cannabinoid receptors and, for the first time, of opioid but not vanilloid receptors, in the neuroprotection, against cerebral ischaemia, induced by THC and AM 404. For these findings to be relevant to a clinical situation, further studies are needed to verify if a delayed administration of these drugs (from 30min to 3h after ischaemia) still produces neuroprotection.
Abbreviations
CB1 cannabinoid receptor type 1
TRPV1 transient receptor potential vanilloid type-1
Notes
Conflict of interest
The authors state no conflict of interest.
References
Akabori H, Yamamoto H, Tsuchihashi H, Mori T, Fujino K, Shimizu T, et al. Transient receptor potential vanilloid 1 antagonist, capsazepine, improves survival in a rat hemorrhagic shock model. Ann Surg. 2007;245:964—970. [PMC free article] [PubMed]
Araki H, Nojiri M, Kawashima K, Kimura M, Aihara H. Behavioral, electroencephalographic and histopathological studies on mongolian gerbils with occluded common carotid arteries. Physiol Behav. 1986;38:89—94. [PubMed]
Bahr BA, Karanian DA, Makanji SS, Makriyannis A. Targeting the endocannabinoid system in treating brain disorders. Expert Opin Investig Drugs. 2006;15:351—365.
Battista N, Fezza F, Finazzi-Agro A, Maccarrone M. The endocannabinoid system in neurodegeneration. Ital J Biochem. 2006;55:283—289. [PubMed]
Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G, et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci. 2000;20:3401—3407. [PubMed]
Beltramo M, Piomelli D. Anandamide transport inhibition by the vanilloid agonist olvanil. Eur J Pharmacol. 1999;364:75—78. [PubMed]
Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. NeuroReport. 2000;11:1231—1235. [PubMed]
Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277:1094—1097. [PubMed]
Berrendero F, Mendizabal V, Murtra P, Kieffer BL, Maldonado R. Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. Eur J Neurosci. 2003;18:2197—2202. [PubMed]
Block F. Global ischemia and behavioural deficits. Prog Neurobiol. 1999;58:279—295. [PubMed]
Bloom AS, Dewey WL. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl) 1978;57:243—248. [PubMed]
Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol. 2004;506:63—69. [PubMed]
Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, Sala M. Post-ischemic treatment with cannabidiol prevents electro-encephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett. 2003;346:61—64. [PubMed]
Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience. 2001;104:923—926. [PubMed]
Braida D, Pozzi M, Sala M. CP 55,940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci Lett. 2000;296:69—72. [PubMed]
Calignano A, La Rana G, Beltramo M, Makriyannis A, Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol. 1997;337:R1—R2. [PubMed]
Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007;28:180—187. [PubMed]
Chen J, Lee CT, Errico S, Deng X, Cadet JL, Freed WJ. Protective effects of delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death. Brain Res Mol Brain Res. 2005;134:215—225. [PMC free article] [PubMed]
Chen Y, Buck J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther. 2000;293:807—812. [PubMed]
Colbourne F, Corbett D. Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of neuroprotection. J Neurosci. 1995;15:7250—7260. [PubMed]
Colbourne F, Li H, Buchan AM. Indefatigable CA1 sector neuroprotection with mild hypothermia induced 6h after severe forebrain ischemia in rat. J Cereb Blood Flow Metab. 1999;19:742—749. [PubMed]
Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M, et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol. 2006;148:1022—1032. [PMC free article] [PubMed]
de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, et al. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol. 2006;16:7—18. [PubMed]
El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, Roon P, et al. Neuroprotective effect of (−)delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol. 2003;163:1997—2008. [PMC free article] [PubMed]
Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol. 1998;38:179—200. [PubMed]
Fernandez-Espejo E, Caraballo I, Rodriguez de Fonseca F, Ferrer B, El Banoua F, Flores JA, et al. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology. 2004;29:1134—1142. [PubMed]
Fernandez-Espejo E, Galan-Rodriguez B. Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacology. 2004;175:220—224. [PubMed]
Garcia-Arencibia M, Gonzalez S, de Lago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007;1134:162—170. [PubMed]
Gilbert GL, Kim HJ, Waataja JJ, Thayer SA. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res. 2007;1128:61—69. [PubMed]
Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther. 2001;298:7—14. [PubMed]
Giuffrida A, Rodriguez de Fonseca FR, Nava F, Loubet-Lescoulie P, Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol. 2000;408:161—168. [PubMed]
Gonzalez S, Romero J, de Miguel R, Lastres-Becker I, Villanua MA, Makriyannis A, et al. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci. 1999;65:327—336. [PubMed]
Hail N., Jr Mechanisms of vanilloid-induced apoptosis. Apoptosis. 2003;8:251—262. [PubMed]
Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (−) delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998;95:8268—8273.
Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci USA. 2000;899:274—282.
Hickey RW, Ferimer H, Alexander HL, Garman RH, Callaway CW, Hicks S, et al. Delayed, spontaneous hypothermia reduces neuronal damage after asphyxial cardiac arrest in rats. Crit Care Med. 2000;28:3511—3516. [PubMed]
Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB(1) receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol. 2005;15:593—599. [PubMed]
Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther. 2000;294:27—32. [PubMed]
Hunter AJ, Green AR, Cross AJ. Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs. Trends Pharmacol Sci. 1995;16:123—128. [PubMed]
Hunter AJ, Mackay KB, Rogers DC. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents. Trends Pharmacol Sci. 1998;19:59—66. [PubMed]
Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci. 2005;25:7813—7820. [PubMed]
Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther. 2007;322:1059—1066. [PubMed]
Katoh A, Ishibashi C, Shiomi T, Takahara Y, Eigyo M. Ischemia-induced irreversible deficit of memory function in gerbils. Brain Res. 1992;577:57—63. [PubMed]
Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, Abouzid K, et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem. 1996;39:4515—4519. [PubMed]
Kirino T, Sano K. Selective vulnerability in the gerbil hippocampus following transient ischemia. Acta Neuropathol. 1984;62:201—208. [PubMed]
Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007;445:643—647. [PubMed]
Kreutz S, Koch M, Ghadban C, Korf HW, Dehghani F. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp Neurol. 2007;203:246—257. [PubMed]
Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis. 2005;19:96—107. [PubMed]
Loskota WJ, Lomax PL, Verity MA. A Stereotaxic Atlas of Mogolian Gerbil (Meriones Unguiculatus) Ann Arbor Science Publishers: Ann Arbor, MI; 1974. pp. 1—157.
Louw DF, Yang FW, Sutherland GR. The effect of Δ-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 2000;857:183—187. [PubMed]
Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem. 2000;275:31938—31945. [PubMed]
Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci. 1999;20:287—294. [PubMed]
Marinelli S, Vaughan CW, Christie MJ, Connor M. Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol. 2002;543:531—540. [PMC free article] [PubMed]
Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem. 2002;80:448—456. [PubMed]
Mathew RJ, Wilson WH, Davis R. Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav. 2003;75:309—318. [PubMed]
McFarland MJ, Barker EL. Anandamide transport. Pharmacol Ther. 2004;104:117—135. [PubMed]
Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, et al. Not too excited? Thank your endocannabinoids. Neuron. 2006;51:393—395. [PubMed]
O'Neill MJ, Clemens JA. Preclinical models of neurologic and psychiatric disorders Current Protocols in Neuroscience 2000. Wiley: New York; 9.5.1—9.5.25.In: Crawley JN, Gerfen CR, Mckay R, Rogawski MA, Sibley DR, Skolnick P (eds).
Panikashvili D, Shein A, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood—brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis. 2006;22:257—264. [PubMed]
Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther. 2006;318:304—311. [PubMed]
Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. Endocannabinoid signalling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology. 2004;145:5431—5438. [PubMed]
Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br J Pharmacol. 2005;144:727—735. [PMC free article] [PubMed]
Pegorini S, Zani A, Braida D, Guerini-Rocco C, Sala M. Vanilloid VR1receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol. 2006;147:552—559. [PMC free article] [PubMed]
Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther. 2002;95:165—174. [PubMed]
Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005;7:E625—E654. [PMC free article] [PubMed]
Peruche B, Klaassens H, Krieglstein J. Quantitative analysis of the electrocorticogram after forebrain ischemia in the rat. Pharmacology. 1995;50:229—237. [PubMed]
Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA. 1999;96:5802—5807.
Rawls SM, Ding Z, Cowan A. Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. Pharmacol Biochem Behav. 2006;83:508—516. [PubMed]
Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005;40:2—14. [PubMed]
Rotilio J, Stella AM. Molecular basis of neurodegenerative diseases. Ital J Biochem. 2006;55:189—193. [PubMed]
Sala M, Leone MP, Lampugnani P, Matturri L, Gori E. Polydeoxyribonucleotide (defibrotide) protects against post-ischemic behavioral, electroencephalographic and neuronal damage in the gerbil. Eur J Pharmacol. 1997;328:143—152. [PubMed]
Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord. 2005;4:677—684. [PubMed]
Schmidt-Kastner R, Hossmann KA. Distribution of ischemic neuronal damage in the dorsal hippocampus of rat. Acta Neuropathol. 1988;76:411—421. [PubMed]
Smith ML, Auer RN, Siesjö BK. The density and distribution of ischemic brain injury in the rat following 2—10min of forebrain ischemia. Acta Neuropathol. 1984;64:319—332. [PubMed]
Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. Eur J Neurosci. 2004;19:3183—3192. [PubMed]
Suzuki R, Yamaguchi T, Kirino T, Orzi F, Klatzo I. The effects of 5-minute ischemia in Mongolian gerbils: I. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes. Acta Neuropathol. 1983;60:207—216. [PubMed]
Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159—212. [PubMed]
Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, et al. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry. 2006;59:508—515. [PubMed]
Veldhuis WB, van der Stelt M, Wadman MW, van Zadelhoff G, Maccarrone M, Fezza F, et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J Neurosci. 2003;23:4127—4133. [PubMed]
Volpe BT, Hirst W. The characterization of an amnesic syndrome following hypoxic ischemic injury. Arch Neurol. 1983;40:436—440. [PubMed]
Yue HY, Fujita T, Kawasaki Y, Kumamoto E. AM404 enhances the spontaneous release of L-glutamate in a manner sensitive to capsazepine in adult rat substantia gelatinosa neurones. Brain Res. 2004;1018:283—287. [PubMed]
Zola-Morgan S, Squire LR, Amaral DG. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci. 1986;6:2950—2967. [PubMed]
Zygmunt PM, Chuang H, Movahed P, Julius D, Hogestatt ED. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol. 2000;396:39—42. [PubMed]
Zygmunt PM, Petersson J, Andersson DA, Chuang H, SørgÃ¥rd M, Di Marzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452—457. [PubMed]
Source with Charts, Graphs and Links: ÃŽ"9-Tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors
A Zani,1 D Braida,1 V Capurro,1 and M Sala1*
1Department of Pharmacology, Chemotherapy and Medical Toxicology, Faculty of Sciences, University of Milan, Milan, Italy
*Author for correspondence: Email: mariaelvina.sala@unimi.it
Received July 25, 2007; Revised September 7, 2007; Accepted September 18, 2007.
Abstract
Background and purpose:
It has been suggested that the endocannabinoid system elicits neuroprotection against excitotoxic brain damage. In the present study the therapeutic potential of AM 404 on ischaemia-induced neuronal injury was investigated in vivo and compared with that of the classical cannabinoid receptor type 1 (CB1) agonist, Δ9-tetraydrocannabinol (THC), using a model of transient global cerebral ischaemia in the gerbil.
Experimental approach:
The effects of AM 404 (0.015—2mgkg−1) and THC (0.05—2mgkg−1), given 5min after ischaemia, were measured from 1h to 7 days in terms of electroencephalographic (EEG) total spectral power, spontaneous motor activity, memory function, rectal temperature and hippocampal CA1 neuronal count.
Key results:
Over the dose range tested, AM 404 (2mgkg−1) and THC (1mgkg−1) completely reversed the ischaemia-induced behavioural, EEG and histological damage. Only THC (1 and 2mgkg−1) induced a decrease of body temperature. Pretreatment with the selective CB1 receptor antagonist, AM 251 (1mgkg−1) and the opioid antagonist, naloxone (2mgkg−1) reversed the protective effect induced by both AM 404 and THC while the TRPV1 vanilloid antagonist, capsazepine (0.01mgkg−1), was ineffective.
Conclusions and implications:
Our findings demonstrate that AM 404 and THC reduce neuronal damage caused by bilateral carotid occlusion in gerbils and that this protection is mediated through an interaction with CB1 and opioid receptors. Endocannabinoids might form the basis for the development of new neuroprotective drugs useful for the treatment of stroke and other neurodegenerative pathologies.
Keywords: (Endo)cannabinoid, vanilloid, ischaemia, electroencephalogram, memory, motor activity, rectal temperature
Introduction
The therapeutic potential of the endocannabinoid system is yet to be fully determined, and the number of diseases that may be treated by interacting with this system will probably continue to grow (Sarne and Mechoulam, 2005; Bahr et al., 2006; Centonze et al., 2007). Until now the endocannabinoid system has been evaluated as a possible target for the treatment of several neurological disorders including Parkinson's disease (Lastres-Becker et al., 2005; Garcia-Arencibia et al., 2007; Kreitzer and Malenka, 2007), Huntington's disease (de Lago et al., 2006), neurodegeneration (Battista et al., 2006; Monory et al., 2006; Rotilio and Stella, 2006) and disorders associated with excessive excitatory neuronal activity, such as epilepsy. Endocannabinoids directly target hippocampal glutamatergic neurons to provide protection against acute epileptiform seizures in mice (Monory et al., 2006).
Special attention has been paid to the mechanism of endocannabinoid uptake through which the biological activity of endocannabinoids ceases (McFarland and Barker, 2004). These compounds, termed indirect agonists, act by potentiating the action of endogenous ligands, and hence they may be used in diseases where an increase in endocannabinoid transmission has been postulated to be of therapeutic value (Giuffrida et al., 2001; Pertwee, 2002). It may be possible to use these compounds to minimize the unwanted effects produced by the direct activation of cannabinoid receptor type 1 (CB1) receptors by classical cannabinoids, through the control of endocannabinoid levels in a concentration range that avoids psychoactive side-effects (Felder and Glass, 1998). One of these compounds, N-(4- hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (AM 404), an inhibitor of anandamide cellular reuptake and inactivation (Khanolkar et al., 1996; Beltramo et al., 1997), has been shown to provide some relief of symptoms associated with neurological disorders. AM404 produced a marked recovery of 6-hydroxydopamine-induced dopamine depletion and tyrosine hydroxylase deficit in the lesioned side of rats submitted to unilateral lesions of nigrostriatal dopaminergic neurons, induced by local application of 6-hydroxydopamine (Pertwee, 2005). Amelioration of akinesia and sensorimotor orientation and reduction of amphetamine-induced turning behaviour in 6-hydroxydopamine-lesioned rats has also been observed after an injection of AM 404 (Fernandez-Espejo et al., 2004). AM 404 significantly decreased restraint-induced serum corticosterone release in mice, suggesting a role of the endocannabinoid system in the signs of environmental stress (Patel et al., 2004; Patel and Hillard, 2006). AM 404 has also been shown to inhibit the anandamide transporter in rat brain neurons and slices (Beltramo et al., 1997; Beltramo and Piomelli, 2000) and human astrocytoma cells (Piomelli et al., 1999) in vitro. When given intravenously, AM 404 induced vasodilatation (Calignano et al., 1997) in guinea-pigs and enhanced and prolonged anandamide-induced analgesia (Beltramo et al., 1997) in mice, in vivo. However, exogenously administered AM404 did not elicit catalepsy or analgesia in rats (Beltramo et al., 2000), but was found to potentiate the effects of anandamide (Rodriguez de Fonseca et al., 2005). In Wistar rats, treatment with AM 404, at a dose of 10mgkg−1, was found to have a hypokinetic effect which was reversed by the CB1 receptor antagonist, rimonabant (Giuffrida et al., 2000). In addition, AM 404 (5mgkg−1) has been found to act as a psychodysleptic drug, altering prepulse inhibition in mice through a cannabinoid CB1 receptor (Fernandez-Espejo and Galan-Rodriguez, 2004) and elicit antidepressant-like effects in the forced swimming test in rats (Hill and Gorzalka, 2005).
There is some evidence from experiments with mice that increasing anandamide or 2-arachidonoyl glycerol content may lead to neuroprotection. After an excitotoxic insult in rat hippocampal slices, an infusion of the fatty acid amide hydrolase inhibitor palmitylsulphonyl fluoride (AM374) and AM404, in combination, protected against cytoskeletal damage and synaptic decline (Karanian et al., 2005, 2007). AM404 per se elicited cytoskeletal and synaptic protection in vivo when coinjected with excitotoxin into the dorsal hippocampus. The potentiated endocannabinoid responses also prevented alterations in behaviour and memory impairment that are characteristics of excitotoxic damage. These protective effects were blocked by a selective CB1 antagonist. The endocannabinoid 2-arachidonoyl glycerol is released in mouse brain after closed head injury, and treatment with exogenous 2-arachidonoyl glycerol exerts neuroprotection via the central CB1 receptor (Panikashvili et al., 2006).
AM404, structurally similar to transient receptor potential vanilloid type-1 (TRPV1) vanilloid receptor agonists, anandamide and capsaicin, may also activate vanilloid TRPV1 receptors (Zygmunt et al., 2000) and, then, exhibit direct effects by itself (Gonzalez et al., 1999; Beltramo and Piomelli, 1999). Capsaicin has been shown to effect neuroprotection through the activation of TRPV1 vanilloid receptors in a model of transient cerebral ischaemia in gerbils (Pegorini et al., 2005, 2006).
The aim of the present work was to assess the therapeutic potential of AM 404 in vivo, and compare its effects with those of the classical CB1 receptor agonist, Δ9-tetraydrocannabinol (THC), on ischaemia-induced neuronal injury using a model of transient global cerebral ischaemia in the gerbil. In principle, we aimed to inject the drugs 5min after ischaemia, as previously performed for other cannabinoid and vanilloid agonists (Braida et al., 2001, 2003; Pegorini et al., 2005, 2006) in order to compare their potential neuroprotective effects with those of previously tested drugs. To quantify the ischaemic damage, from 1h to 7 days after reperfusion, we measured different parameters known to be influenced by global cerebral ischaemia: electroencephalogram (EEG) spectral power, spontaneous motor activity, memory function and hippocampal CA1 neuronal count. We measured motor activity on day 1, since ischaemia-induced hyperlocomotion is maximal 24h after occlusion (Araki et al., 1986), memory function on day 3 according to Sala et al. (1997). Since the decrease in electroencephalogram has been related to pronounced damage of neurons on day 7 (Suzuki et al., 1983; Hunter et al., 1995; Peruche et al., 1995), EEG spectral power and neuronal counts were measured at that time. In addition, receptor antagonists were used to investigate a potential role for CB1, opioid and TRPV1 receptors. Collectively, our data demonstrate that AM 404 and THC protect against neuronal ischaemia-induced injury through a mechanism involving cannabinoid and opioid receptors but not vanilloid receptors.
Methods
Animals
Male Mongolian gerbils (Meriones unguiculatus) (Charles River, Calco, Como, Italy) weighing 60—80g were housed singly in standard laboratory conditions: air-conditioned room (22±2°C), 12-h light/12-h dark light cycle, free access to food and water. The gerbils were allowed to acclimatize themselves to the environment for 1 week before surgical implantation of cortical electrodes. After the EEG electrodes had been implanted, the gerbils were divided into different groups on the basis of the treatment assigned. Each animal received all tests. All procedures were approved under the Italian Governmental decree no. 32/2004.
Surgical procedure
Gerbils were anaesthetized with an i.p. injection of chloral hydrate (450mgkg−1) dissolved in saline and given in a volume of 9mlkg−1. Four electrodes (Bilaney, Dusseldorf, Germany) were implanted for EEG recordings, as described previously (Sala et al., 1997), on the right and left of the parieto-occipital cortex according to brain atlas coordinates (anterior +2, posterior −3, lateral 2, ventral 1.6 from bregma) (Loskota et al., 1974). Another electrode was inserted into the nasal bone as a reference location. The five electrodes were connected to a pedestal (Bilaney) and fixed with acrylic cement. The animals were allowed a week to recover from surgery before the experiments were started.
EEG recording
Freely moving, awake gerbils were acclimatized in a sound-proofed Faraday chamber, then their electroencephalogram was recorded for 1h a day, for 3 days, to determine the basal total and relative spectral power. The signals were recorded and processed for fast Fourier transform spectral analysis by means of PC software (PowerLab, AD Instruments Pty Ltd, Castle Hill, NSW, Australia). Electroen Cephalograph (EEG) recordings were also made during and 7 days after ischaemia. Each 1-h spectral power was calculated as the mean of six 1-min recordings taken at 10-min intervals.
Cerebral ischaemia
After basal EEG recordings, each gerbil was again lightly anaesthetized with 2,2,2- tribromoethanol (200mgkg−1, 10mlkg−1). Throughout surgery, body temperature was kept at 37°C with a heating lamp and 10-min period of ischaemia was induced by occlusion of the bilateral common carotid arteries, as described previously (Braida et al., 2000). The ischaemia was verified qualitatively on paper by the complete absence of the electroencephalogram. A group of animals (sham-operated) underwent the same surgical procedure except that the carotid arteries were not clamped.
Locomotor activity
Spontaneous motor activity was evaluated as described previously (Braida et al., 2000) in an activity cage (43cm long × 43cm wide × 32cm high: Ugo Basile, Varese, Italy), placed in a sound-proofed room. The cage was fitted with two parallel horizontal infrared beams 2cm off the floor. Cumulative horizontal movements were counted every 5min for 30min, 1 day after ischaemia.
Passive avoidance task
On the third day after ischaemia, each gerbil was examined in the passive avoidance task. The apparatus (Ugo Basile) consisted of a box divided by a guillotine door into two compartments of the same size (22cm long × 22cm wide × 21cm high) in which the floor was a stainless rod grid. One compartment was lit with a 10W electric light bulb, while the other was dark. The step-through type passive avoidance task was used, as described by Katoh et al. (1992), with some modifications. Animals were allowed to adapt for 10min before the training, and retention was checked 24h after the training. For the adaptation a gerbil was placed in the light compartment, and allowed to explore both compartments by leaving the guillotine door open for 5min. After 10min, the training period was started during which each gerbil was placed in the light compartment and allowed to enter the dark. When the gerbil entered the dark compartment, the door automatically closed and an unavoidable scrambled foot shock (1.5mA) was delivered for 5s. Each gerbil then stayed there for 10s. The procedure was immediately repeated twice. For the retention test, gerbils were placed in the light compartment and the latency period before they re-entered the dark compartment was recorded for up to 180s.
Body temperature
The experiments were performed in the sound-proofed Faraday chamber. Controls, sham-operated and ischaemic gerbils were trained to accept the temperature measurements for 5 days before thermoregulator reactions were tested, as described by Sala et al. (1997). Briefly, after a 1-h acclimatization period in the test room, maintained at 22°C, body temperature was monitored with a rectal thermistor probe (PRA-22002-A, Ellab, Roedovre, Denmark) inserted 3cm into the colon. After a 30-s equilibration period, the temperature was recorded to the nearest 0.11°C on a CTD 85-M Thermometer (Ellab). During temperature measurements, gerbils were unrestrained and were held gently by hand at the base of the tail. Temperature was measured three times (every 10min) before induction of ischaemia (basal) and again at 30, 60, 90 and 120min after recirculation.
Histology
Seven days after the ischaemic injury, all the gerbils were killed by an overdose of chloral hydrate 5% and transcardially perfused with 4% paraformaldehyde for determining histological data, as described previously (Braida et al., 2003). Brains were removed and placed in the same fixative overnight, then embedded in paraffin wax. Five serial 5-μm coronal hippocampal sections for each animal were cut at 1.5, 1.7 and 1.9mm caudal to the bregma, using a microtome (Leica, Mod. RM2125RT, Solms, Germany), and stained with cresyl violet. Neurons with a normal appearance in the pyramidal cell layer of the CA1 sector were counted blind (from coded slides) in each section for each group.
Experimental design
Gerbils submitted to ischaemia were divided into different groups, receiving acutely: vehicle+vehicle; vehicle+AM 404 (0.015, 0.03, 0.1, 0.5, 1, 2mgkg−1); AM 251 (1mgkg−1)+vehicle; AM 251+AM 404 (2mgkg−1); capsazepine (0.01mgkg−1)+vehicle; capsazepine+AM 404 (2mgkg−1); naloxone (2mgkg−1)+vehicle; naloxone+AM 404 (2mgkg−1); vehicle+THC (0.05, 0.1, 0.5, 1, 2mgkg−1); AM 251+THC (1mgkg−1); capsazepine+THC (1mgkg−1) and naloxone+THC (1mgkg−1). AM 404 and THC were injected i.p. 5min after recirculation; capsazepine was given s.c. 15min before bilateral carotid occlusion, while AM 251 and naloxone were given i.p. 5min before. Vehicle was given 15 or 5min before or 5min after ischaemia, either s.c. or i.p. Drugs were dissolved in an appropriate vehicle (90% saline–10% (dimethylsulphoxide) for AM 404 and AM 251; cremophor, ethanol, saline 1
18 for THC; Tween-80, ethanol, saline, 18 for capsazepine; saline for naloxone) and injected in a volume of 1mlkg−1 s.c. and 5mlkg−1 i.p. The sham-operated group received the same volume of vehicle. The dose of capsazepine used was chosen on the basis of our previous work (Pegorini et al., 2006), where it reversed the neuroprotection induced by capsaicin. The dose of naloxone used was able to antagonize the rewarding effects produced by heroin (Braida et al., 2001) and THC (Braida et al., 2004), while that of AM 251 reversed the anxiolytic effect induced by THC and AM 404 (unpublished data).Statistical analysis
Data are presented as mean (±s.e.m.). Vehicle groups (s.c. and i.p) were pooled for analysis. Total EEG spectral data are expressed as the mean difference (%) from the pre-ischaemic values. Total spectral power, motor activity, latency time and neuronal counts were analysed by one- or two-way analysis of variance (ANOVA) for multiple comparisons, followed by Tukey's or Student's t-test. The accepted level of significance was P<0.05. All statistical analyses were carried out using Prism, version 4 software (GraphPad, USA).
Drugs, materials and sources
AM 404, AM 251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide), chloral hydrate, 2,2,2-tribromoethanol, paraformaldehyde, cresyl violet, naloxone and THC (Sigma Aldrich, St Louis, MO, USA); capsazepine (Tocris Bioscience, Bristol, UK); acrylic cement (Palavit, New Galetti and Rossi, Milan, Italy).
Results
Physiological parameters–food and water consumption and body weight (76.20±0.38g)–were stable throughout the study in all groups (data not shown).
EEG recordings
Seven days after a 10-min period of carotid occlusion and treatment with AM 404 or THC 5min after recirculation, a quantitative EEG analysis was performed in the ischaemic and sham-operated gerbils (Figures 1a and b). Significant between-group differences were
observed in terms of the percentages of the pre-ischaemic values of mean total spectral power, evaluated on day 7 after AM 404 (F(12,52)=28.27, P<0.0001, ANOVA) and THC (F(12,52)=11.49, P<0.0001, ANOVA) treatment. Post hoc analysis revealed that, in comparison with sham-operated values, the vehicle group had a decrease of EEG power of about 80%. AM404, at all the doses tested, while THC, in a range between 0.1 and 1mgkg−1, significantly antagonized the ischaemia-induced EEG flattening. Pretreatment with naloxone (2mgkg−1) completely, while pretreatment with AM 251 (1mgkg−1) or capsazepine (0.01mgkg−1) only slightly, blocked the protective effect of AM404 obtained at 2mgkg−1. Post hoc test showed that both AM 251 and naloxone, but not capsazepine, reversed the protective effect of THC. The three antagonists per se did not induce any changes, when compared with the vehicle group. Figure 1
Cortically derived EEG total spectral power evaluated on day 7, as the difference (Δ%) from the pre-ischaemic value in freely moving, awake gerbils given increasing doses (mgkg−1) of AM 404 (a) and THC (b), 5min (more ...)
Spontaneous locomotor activity
There were significant between-group changes in spontaneous locomotor activity 1 day after ischaemia in gerbils treated with AM 404 or THC (Figures 2a and b). ANOVA revealed significant differences
between groups after AM404 (F(12,52)=35.32, P<0.0001) and THC (F(12,52)=17.95, P<0.0001) treatment. Post hoc comparison revealed an increase in locomotor activity in the vehicle group compared to the sham-operated group, whereas a complete recovery in the activity levels was observed, at all the tested doses, in the AM 404 and THC-treated animals. Naloxone and AM 251 reversed the protective effect of AM 404 (2mgkg−1) but capsazepine had no effect. When combined with THC (1mgkg−1), AM 251 induced a partial but significant antagonism of the effects of THC. Capsazepine and naloxone failed to block the protective effect of THC. The three antagonists per se did not affect hyperlocomotion. Figure 2
Effect of increasing doses (mgkg−1) of AM 404 (a) and Δ9-THC (b) given i.p. 5min after recirculation on spontaneous motor activity evaluated for 30min, 1 day after ischaemia in gerbils. AM 251 or naloxone (NX) (more ...)
Passive avoidance
Figure 3 shows the mean latency time measured 3 days after
recirculation in ischaemic gerbils treated with increasing doses of AM 404 or THC (Figures 3a and b). There were significant between-group
changes in mean latency time in AM 404 (F(12,52)=6.18, P<0.0001, ANOVA) and THC (F(12,52)=143.9, P<0.0001, ANOVA) groups. Post hoc analysis indicated that vehicle-treated gerbils experienced significant impairment, as shown by the decrease in mean escape latency in comparison with the sham-operated group. AM404 and THC progressively improved, even if only slightly, this memory deficit. Pretreatment with AM 251 and capsazepine did not affect the cognitive improvement induced by AM 404 (2mgkg−1), whereas it was completely antagonized by naloxone (Tukey's test). When AM 251 and naloxone were given in combination with THC (1mgkg−1), complete antagonism of the effect of THC was observed (Tukey's test). Capsazepine failed to block the protective effect of THC. Figure 3
Mean (±s.e.m.) escape latency in the passive avoidance task 3 days after 10-min carotid occlusion. Increasing doses (mgkg−1) of AM 404 (a) and THC (b) given 5min after recirculation. AM 251 or naloxone (NX) was administered, (more ...)
Body temperature
Changes in body temperature were only seen at 30min after the period of ischaemia (2-way ANOVA, followed by Bonferroni's test). Thus, in Table 1 only findings obtained at 30min after ischaemia are presented.
Treatment with AM404 did not affect the mean rectal temperature at any dose tested, but THC did (F(12,52)=10.77, P<0.0001, ANOVA). Post hoc analysis revealed that in THC groups treated with 1 and 2mgkg−1 there was a decrease of body temperature. Pretreatment with AM 251 antagonized THC (1mgkg−1)-induced hypothermic effect while capsazepine and naloxone, which per se did not affect this parameter, were ineffective. Table 1
Effect of AM 404 and THC given alone or in combination with different antagonists on rectal temperature (°C) in gerbils subjected to cerebral ischaemiaa
Histology
Histological examination of the hippocampus at 7 days after recirculation, following 10min of occlusion and 5min of treatment, showed that severe alterations in the CA1 region occurred in the ischaemic group compared to the sham-operated animals (Figure 4).
Most of the pyramidal cells were darkly stained and shrunken. A comparison of the number of neuronal cells counted (using ANOVA) revealed significant differences between the groups (F(8,36)=23.78, P<0.0001 for AM 404 (2mgkg−1); F(8,36) =6.85, P<0.0001 for THC (1mgkg−1)). A post hoc analysis revealed a decreased number of neuronal cells in the vehicle-treated gerbils compared with the sham-operated group and both drugs completely prevented this loss of cells (Figure 5). Pretreatment with naloxone significantly antagonized AM
404-induced neuroprotective effect, whereas AM 251 and capsazepine failed to block it. The three antagonists per se caused a mean decrease in the number of neuronal cells similar to that seen in the vehicle-treated group. Only pretreatment with AM 251 significantly antagonized the neuroprotective affect of THC. Figure 4
Photomicrographs of the hippocampal CA1 region of gerbils with or without 10min ischaemia, 7 days after recirculation. AM 251 and naloxone (NX) were given, i.p., 5min before bilateral carotid occlusion; capsazepine (CPZ) was given, s.c., (more ...)
Figure 5
Effect of AM 404 (a) and THC (b) on neuronal count, performed 7 days after recirculation, in the CA1 region of the hippocampus of sham-operated or ischaemic gerbils. AM 404 and THC were given, i.p., 5min after recirculation. AM 251 or naloxone (more ...)
Discussion
In the present study, using a well-established animal model of ischaemia, we showed that both the exogenous cannabinoid agonist, THC, and the anandamide transporter inhibitor, AM 404, given i.p. after bilateral carotid occlusion, fully protected the animals from the deleterious effects of the ischaemic insult. This neuroprotection was quantified in terms of complete recovery of all the behavioural and EEG parameters. Among them, both cognitive and sensorimotor deficits can be found in some human pathological conditions, such as heart attack and coronary artery bypass surgery (Hunter et al., 1998). Furthermore, the histopathology seen in the gerbil is similar to that observed in the hippocampal CA1 region of human brain following cardiac arrest (Hunter et al., 1995).
Results obtained from EEG mean total spectral analysis indicated that both THC and AM 404 reversed EEG flattening effect (isoelectric electroencephalogram), induced by bilateral carotid occlusion on day 7 after ischaemia. It is known that after transient global ischaemia, EEG drop is indicative of a severe depression of electrophysiological activity and reflects an impairment of cerebral blood flow. Such a decrease has been related to the severe and selective neuronal death appearing in the CA1 layer of the hippocampal formation following an impairment of synaptic activity (Kirino and Sano, 1984; Smith et al., 1984; Zola-Morgan et al., 1986; Schmidt-Kastner and Hossmann, 1988).
Vasodilatation may be involved in the protection against neuronal death on day 7 effected by THC (1mgkg−1) and AM 404 (2mgkg−1). Cannabinoid perfusion increases the diameter of cerebral arterioles and cerebral arteries (Hillard, 2000) in a CB1 receptor-dependent fashion, indicating that the main cerebrovascular effect of cannabinoids is vasodilatation. This accords with findings that marijuana smoking in humans is accompanied by an increase in cerebral blood flow (Mathew et al., 2003). Furthermore, AM 404 has been found to be a vasodilator and activator of TRPV1 receptors expressed in Xenopus oocytes (Zygmunt et al., 2000) and in the rat hepatic artery (Zygmunt et al., 1999).
The full protection against motor hyperactivity seen in both THC and AM 404-treated gerbils indicates that these drugs induce a recovery of the ability of animals to form spatial maps, initially suppressed due to the loss of CA1 neurons, as suggested by O'Neill and Clemens (2000). Any intrinsic effects of the drugs can be excluded, since the evaluation was carried out 24h after treatment.
Both THC and AM 404 dose-dependently prevented ischaemia-induced memory impairment. This condition has been clinically demonstrated during cardiac arrest, revealed as amnesia and characterized by impaired learning and memory of events after the injury (Volpe and Hirst, 1983). The deficits in learning and memory induced by global cerebral ischaemia showed a close correlation with the neuronal death in the hippocampal CA1 region, as suggested by Block (1999). An increase in number of intact CA1 neurons (about 75%) that are most vulnerable to hypoxic insult and involved in learning and memory was observed in THC- and AM 404-treated gerbils subjected to ischaemic insult.
The protective effect of THC was accompanied by a clear hypothermic effect at the highest doses. At present, post-ischaemic hypothermia provides the best long-term functional and histological protection against the effects of global ischaemia (Colbourne and Corbett, 1995; Colbourne et al., 1999; Hickey et al., 2000). However, since THC exhibited neuroprotective effects at both hypothermic and normothermic doses, hypothermia was not a factor in this study. In addition, Louw et al. (2000) found that there was significantly less neocortical injury after induction of global cerebral ischaemia in THC-treated rats when rigorous temperature control was maintained through the experiment.
No change in body temperature was observed in AM 404-treated animals. This is in accordance with the results of Rawls et al. (2006); they demonstrated that this endocannabinoid inhibitor transporter produced a clear hypothermic effect, which required a vanilloid TRPV1 activation, only at doses higher than 10mgkg−1.
The neuroprotection obtained with THC is consistent with previous findings where other cannabinoids, like CP 55940 (Braida et al., 2000) and cannabidiol (Braida et al., 2003), prevented ischaemia-induced damage in the same animal model of ischaemia. In addition, after repeated treatment with THC for 7 days prior to bilateral carotid artery occlusion produced a neuroprotection in rats in vivo, accompanied by a reduction in systolic blood pressure (Louw et al., 2000). In in vitro studies, THC protected neurons against excitotoxic insults, mediated by exposure to the glutamatergic agonists N-methyl-D-aspartate and KA (Hampson et al., 1998; El-Remessy et al., 2003; Chen et al., 2005; Gilbert et al., 2007; Kreutz et al., 2007).
The neuroprotection obtained with AM 404 is in accordance with the findings of Karanian et al. (2005), who reported that the anandamide transporter inhibitor enhanced the action of exogenous anandamide in vitro protecting against excitotoxic damage in hippocampal slice cultures by a mechanism involving CB1 receptors. In addition, AM 404 repeatedly administered for 2 weeks produced a marked recovery of 6-OH-dopamine-induced dopamine depletion in a rat model of Parkinson's disease (Garcia-Arencibia et al., 2007).
The finding that AM 251 prevented neuroprotection induced by both THC and AM 404 indicates that CB1 receptors are involved in this effect. The antagonism by AM 251 of the neuroprotection induced by THC does not agree with the findings of other studies, where the protective actions of THC were mediated primarily or exclusively by effects on chemical antioxidants (Chen and Buck, 2000; Hampson et al., 2000, Marsicano et al., 2002). Therefore, it appears that in some circumstances, THC exerts neuroprotective effects exclusively through non-receptor-mediated antioxidant properties, while in other models stimulation of CB1 receptors by THC or WIN 55212-2 might produce neuroprotection. Differences between the effects observed in different models may be related to the cell type or model system, and to differences in the toxic insults employed.
As expected, capsazepine did not reverse the protective effect of THC. Accordingly, the neuroprotective effect of THC, evaluated in an in vitro model in which the AF5 CNS cell line was exposed to toxic levels of N-methyl-D-aspartate, was not reversed by the TRPV1 antagonist (Chen et al., 2005). In addition, THC-induced suppression of serum interleukin-12 levels in Legionella pneumophila-infected cells was not attenuated by pretreatment with the TRPV1 antagonist.
Although it has been shown that AM 404 binds TRPV1 receptors in the rat isolated hepatic artery (Zygmunt et al., 2000), it is unlikely that this occurred at the doses of this endocannabinoid transporter inhibitor used in our study. Activation of TRPV1 leads to an increased influx of Ca2+ (Szallasi and Blumberg, 1999), glutamate release (Marinelli et al., 2002) and substantial contribution to neuronal excitotoxicity (apoptosis) (Maccarrone et al., 2000; Hail, 2003; Yue et al., 2004). It could be argued that the dose of capsazepine used in the present study was too low to reverse any TRPV1-mediated effects. However, Costa et al. (2006) showed that capsazepine (10mgkg−1) reversed the antihyperalgesic effect of AM 404 in a rat model of neuropathic pain. In addition, Tzavara et al. (2006) found that 5mgkg−1 capsazepine were able to antagonize the normalization of hyperlocomotion induced by AM 404 (3mgkg−1) in a model of hyperdopaminergia in knockout mice. However, in our experiments, using our model of global ischaemia, when the dose was increased (0.05mgkg−1) capsazepine exhibited per se a protective effect (data not shown). This latter finding is in accordance with previous results (Veldhuis et al., 2003) where the vanilloid antagonist per se reduced brain injury caused by excitotoxicity, and when given in a range of doses between 0.005 and 5μmolkg−1 (Akabori et al., 2007) (similar to ours) it significantly improved survival rates in a rat model of haemorrhagic shock.
The opioid antagonist, naloxone, blocked the neuroprotective effect induced by THC in terms of EEG flattening and memory impairment, and that induced by AM 404 on all the parameters evaluated. An interaction between the opioid and endocannabinoid system is not surprising since cannabinoids and opioids share several pharmacological effects, including hypothermia, sedation, analgesia and the inhibition of motor activity (Bloom and Dewey, 1978; Manzanares et al., 1999). Systemic administration of THC increases extracellular levels of the endogenous opioid receptor ligand β-endorphin in both the ventral tegmental area and the nucleus accumbens, and injection of β-endorphin into the ventral tegmental area markedly enhances the ability of rats to discriminate the effects of experimenter-administered THC (Solinas et al., 2004). In addition, it has been shown that CB1 receptors and μ- and δ-opioid receptors in the striatum are strongly linked at the intracellular level (Berrendero et al., 2003). Thus, on the one hand, cannabinoid receptor agonists can release endogenous opioids, and, on the other hand, stimulation of opioid receptors can facilitate the signal transduction of cannabinoid receptors. Therefore, it is likely that opioid agonists facilitate certain effects of THC by mimicking some of the effects of endogenous opioids released by THC and, at the same time, facilitating CB1 receptor-induced effects at the intracellular level. Conversely, the reduction of the protective actions of THC, induced by opioid antagonists, is probably due to blockade of the effects of endogenous opioids released by THC and antagonism of CB1 receptor-mediated effects at the intracellular level.
To summarize, our findings provide further evidence for the involvement of cannabinoid receptors and, for the first time, of opioid but not vanilloid receptors, in the neuroprotection, against cerebral ischaemia, induced by THC and AM 404. For these findings to be relevant to a clinical situation, further studies are needed to verify if a delayed administration of these drugs (from 30min to 3h after ischaemia) still produces neuroprotection.
Abbreviations
CB1 cannabinoid receptor type 1
TRPV1 transient receptor potential vanilloid type-1
Notes
Conflict of interest
The authors state no conflict of interest.
References
Akabori H, Yamamoto H, Tsuchihashi H, Mori T, Fujino K, Shimizu T, et al. Transient receptor potential vanilloid 1 antagonist, capsazepine, improves survival in a rat hemorrhagic shock model. Ann Surg. 2007;245:964—970. [PMC free article] [PubMed]
Araki H, Nojiri M, Kawashima K, Kimura M, Aihara H. Behavioral, electroencephalographic and histopathological studies on mongolian gerbils with occluded common carotid arteries. Physiol Behav. 1986;38:89—94. [PubMed]
Bahr BA, Karanian DA, Makanji SS, Makriyannis A. Targeting the endocannabinoid system in treating brain disorders. Expert Opin Investig Drugs. 2006;15:351—365.
Battista N, Fezza F, Finazzi-Agro A, Maccarrone M. The endocannabinoid system in neurodegeneration. Ital J Biochem. 2006;55:283—289. [PubMed]
Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G, et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci. 2000;20:3401—3407. [PubMed]
Beltramo M, Piomelli D. Anandamide transport inhibition by the vanilloid agonist olvanil. Eur J Pharmacol. 1999;364:75—78. [PubMed]
Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. NeuroReport. 2000;11:1231—1235. [PubMed]
Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277:1094—1097. [PubMed]
Berrendero F, Mendizabal V, Murtra P, Kieffer BL, Maldonado R. Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. Eur J Neurosci. 2003;18:2197—2202. [PubMed]
Block F. Global ischemia and behavioural deficits. Prog Neurobiol. 1999;58:279—295. [PubMed]
Bloom AS, Dewey WL. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl) 1978;57:243—248. [PubMed]
Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol. 2004;506:63—69. [PubMed]
Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, Sala M. Post-ischemic treatment with cannabidiol prevents electro-encephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett. 2003;346:61—64. [PubMed]
Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience. 2001;104:923—926. [PubMed]
Braida D, Pozzi M, Sala M. CP 55,940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci Lett. 2000;296:69—72. [PubMed]
Calignano A, La Rana G, Beltramo M, Makriyannis A, Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol. 1997;337:R1—R2. [PubMed]
Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007;28:180—187. [PubMed]
Chen J, Lee CT, Errico S, Deng X, Cadet JL, Freed WJ. Protective effects of delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death. Brain Res Mol Brain Res. 2005;134:215—225. [PMC free article] [PubMed]
Chen Y, Buck J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther. 2000;293:807—812. [PubMed]
Colbourne F, Corbett D. Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of neuroprotection. J Neurosci. 1995;15:7250—7260. [PubMed]
Colbourne F, Li H, Buchan AM. Indefatigable CA1 sector neuroprotection with mild hypothermia induced 6h after severe forebrain ischemia in rat. J Cereb Blood Flow Metab. 1999;19:742—749. [PubMed]
Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M, et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol. 2006;148:1022—1032. [PMC free article] [PubMed]
de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, et al. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol. 2006;16:7—18. [PubMed]
El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, Roon P, et al. Neuroprotective effect of (−)delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol. 2003;163:1997—2008. [PMC free article] [PubMed]
Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol. 1998;38:179—200. [PubMed]
Fernandez-Espejo E, Caraballo I, Rodriguez de Fonseca F, Ferrer B, El Banoua F, Flores JA, et al. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology. 2004;29:1134—1142. [PubMed]
Fernandez-Espejo E, Galan-Rodriguez B. Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacology. 2004;175:220—224. [PubMed]
Garcia-Arencibia M, Gonzalez S, de Lago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007;1134:162—170. [PubMed]
Gilbert GL, Kim HJ, Waataja JJ, Thayer SA. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res. 2007;1128:61—69. [PubMed]
Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther. 2001;298:7—14. [PubMed]
Giuffrida A, Rodriguez de Fonseca FR, Nava F, Loubet-Lescoulie P, Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol. 2000;408:161—168. [PubMed]
Gonzalez S, Romero J, de Miguel R, Lastres-Becker I, Villanua MA, Makriyannis A, et al. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci. 1999;65:327—336. [PubMed]
Hail N., Jr Mechanisms of vanilloid-induced apoptosis. Apoptosis. 2003;8:251—262. [PubMed]
Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (−) delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998;95:8268—8273.
Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci USA. 2000;899:274—282.
Hickey RW, Ferimer H, Alexander HL, Garman RH, Callaway CW, Hicks S, et al. Delayed, spontaneous hypothermia reduces neuronal damage after asphyxial cardiac arrest in rats. Crit Care Med. 2000;28:3511—3516. [PubMed]
Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB(1) receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol. 2005;15:593—599. [PubMed]
Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther. 2000;294:27—32. [PubMed]
Hunter AJ, Green AR, Cross AJ. Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs. Trends Pharmacol Sci. 1995;16:123—128. [PubMed]
Hunter AJ, Mackay KB, Rogers DC. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents. Trends Pharmacol Sci. 1998;19:59—66. [PubMed]
Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci. 2005;25:7813—7820. [PubMed]
Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther. 2007;322:1059—1066. [PubMed]
Katoh A, Ishibashi C, Shiomi T, Takahara Y, Eigyo M. Ischemia-induced irreversible deficit of memory function in gerbils. Brain Res. 1992;577:57—63. [PubMed]
Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, Abouzid K, et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem. 1996;39:4515—4519. [PubMed]
Kirino T, Sano K. Selective vulnerability in the gerbil hippocampus following transient ischemia. Acta Neuropathol. 1984;62:201—208. [PubMed]
Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007;445:643—647. [PubMed]
Kreutz S, Koch M, Ghadban C, Korf HW, Dehghani F. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp Neurol. 2007;203:246—257. [PubMed]
Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis. 2005;19:96—107. [PubMed]
Loskota WJ, Lomax PL, Verity MA. A Stereotaxic Atlas of Mogolian Gerbil (Meriones Unguiculatus) Ann Arbor Science Publishers: Ann Arbor, MI; 1974. pp. 1—157.
Louw DF, Yang FW, Sutherland GR. The effect of Δ-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 2000;857:183—187. [PubMed]
Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem. 2000;275:31938—31945. [PubMed]
Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci. 1999;20:287—294. [PubMed]
Marinelli S, Vaughan CW, Christie MJ, Connor M. Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol. 2002;543:531—540. [PMC free article] [PubMed]
Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem. 2002;80:448—456. [PubMed]
Mathew RJ, Wilson WH, Davis R. Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav. 2003;75:309—318. [PubMed]
McFarland MJ, Barker EL. Anandamide transport. Pharmacol Ther. 2004;104:117—135. [PubMed]
Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, et al. Not too excited? Thank your endocannabinoids. Neuron. 2006;51:393—395. [PubMed]
O'Neill MJ, Clemens JA. Preclinical models of neurologic and psychiatric disorders Current Protocols in Neuroscience 2000. Wiley: New York; 9.5.1—9.5.25.In: Crawley JN, Gerfen CR, Mckay R, Rogawski MA, Sibley DR, Skolnick P (eds).
Panikashvili D, Shein A, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood—brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis. 2006;22:257—264. [PubMed]
Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther. 2006;318:304—311. [PubMed]
Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. Endocannabinoid signalling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology. 2004;145:5431—5438. [PubMed]
Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br J Pharmacol. 2005;144:727—735. [PMC free article] [PubMed]
Pegorini S, Zani A, Braida D, Guerini-Rocco C, Sala M. Vanilloid VR1receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol. 2006;147:552—559. [PMC free article] [PubMed]
Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther. 2002;95:165—174. [PubMed]
Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005;7:E625—E654. [PMC free article] [PubMed]
Peruche B, Klaassens H, Krieglstein J. Quantitative analysis of the electrocorticogram after forebrain ischemia in the rat. Pharmacology. 1995;50:229—237. [PubMed]
Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA. 1999;96:5802—5807.
Rawls SM, Ding Z, Cowan A. Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. Pharmacol Biochem Behav. 2006;83:508—516. [PubMed]
Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005;40:2—14. [PubMed]
Rotilio J, Stella AM. Molecular basis of neurodegenerative diseases. Ital J Biochem. 2006;55:189—193. [PubMed]
Sala M, Leone MP, Lampugnani P, Matturri L, Gori E. Polydeoxyribonucleotide (defibrotide) protects against post-ischemic behavioral, electroencephalographic and neuronal damage in the gerbil. Eur J Pharmacol. 1997;328:143—152. [PubMed]
Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord. 2005;4:677—684. [PubMed]
Schmidt-Kastner R, Hossmann KA. Distribution of ischemic neuronal damage in the dorsal hippocampus of rat. Acta Neuropathol. 1988;76:411—421. [PubMed]
Smith ML, Auer RN, Siesjö BK. The density and distribution of ischemic brain injury in the rat following 2—10min of forebrain ischemia. Acta Neuropathol. 1984;64:319—332. [PubMed]
Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. Eur J Neurosci. 2004;19:3183—3192. [PubMed]
Suzuki R, Yamaguchi T, Kirino T, Orzi F, Klatzo I. The effects of 5-minute ischemia in Mongolian gerbils: I. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes. Acta Neuropathol. 1983;60:207—216. [PubMed]
Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159—212. [PubMed]
Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, et al. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry. 2006;59:508—515. [PubMed]
Veldhuis WB, van der Stelt M, Wadman MW, van Zadelhoff G, Maccarrone M, Fezza F, et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J Neurosci. 2003;23:4127—4133. [PubMed]
Volpe BT, Hirst W. The characterization of an amnesic syndrome following hypoxic ischemic injury. Arch Neurol. 1983;40:436—440. [PubMed]
Yue HY, Fujita T, Kawasaki Y, Kumamoto E. AM404 enhances the spontaneous release of L-glutamate in a manner sensitive to capsazepine in adult rat substantia gelatinosa neurones. Brain Res. 2004;1018:283—287. [PubMed]
Zola-Morgan S, Squire LR, Amaral DG. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci. 1986;6:2950—2967. [PubMed]
Zygmunt PM, Chuang H, Movahed P, Julius D, Hogestatt ED. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol. 2000;396:39—42. [PubMed]
Zygmunt PM, Petersson J, Andersson DA, Chuang H, SørgÃ¥rd M, Di Marzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452—457. [PubMed]
Source with Charts, Graphs and Links: ÃŽ"9-Tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors
